Envestnet Asset Management’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.3M | Sell |
67,942
-116
| -0.2% | -$5.64K | ﹤0.01% | 2489 |
|
|
2025
Q1 | $2.32M | Buy |
68,058
+12,025
| +21% | +$409K | ﹤0.01% | 2626 |
|
|
2024
Q4 | $2.21M | Buy |
56,033
+1,256
| +2% | +$49.4K | ﹤0.01% | 2631 |
|
|
2024
Q3 | $2.57M | Buy |
54,777
+14,131
| +35% | +$664K | ﹤0.01% | 2502 |
|
|
2024
Q2 | $2.2M | Sell |
40,646
-671
| -2% | -$36.2K | ﹤0.01% | 2544 |
|
|
2024
Q1 | $2.82M | Buy |
41,317
+1,930
| +5% | +$132K | ﹤0.01% | 2359 |
|
|
2023
Q4 | $2.47M | Buy |
39,387
+10,767
| +38% | +$674K | ﹤0.01% | 2335 |
|
|
2023
Q3 | $1.3M | Buy |
28,620
+10,607
| +59% | +$481K | ﹤0.01% | 2619 |
|
|
2023
Q2 | $1.01M | Sell |
18,013
-1,527
| -8% | -$85.7K | ﹤0.01% | 2738 |
|
|
2023
Q1 | $884K | Sell |
19,540
-4,945
| -20% | -$224K | ﹤0.01% | 2759 |
|
|
2022
Q4 | $995K | Buy |
24,485
+2,643
| +12% | +$107K | ﹤0.01% | 2648 |
|
|
2022
Q3 | $1.43M | Buy |
21,842
+14
| +0.1% | +$915 | ﹤0.01% | 2291 |
|
|
2022
Q2 | $1.33M | Buy |
21,828
+2,739
| +14% | +$166K | ﹤0.01% | 2379 |
|
|
2022
Q1 | $1.2M | Buy |
19,089
+2,668
| +16% | +$167K | ﹤0.01% | 2543 |
|
|
2021
Q4 | $1.24M | Buy |
16,421
+566
| +4% | +$42.9K | ﹤0.01% | 2480 |
|
|
2021
Q3 | $1.78M | Sell |
15,855
-5,736
| -27% | -$642K | ﹤0.01% | 2164 |
|
|
2021
Q2 | $3.5M | Buy |
21,591
+5,656
| +35% | +$916K | ﹤0.01% | 1725 |
|
|
2021
Q1 | $1.94M | Buy |
15,935
+6,457
| +68% | +$787K | ﹤0.01% | 1954 |
|
|
2020
Q4 | $1.45M | Buy |
9,478
+5,452
| +135% | +$835K | ﹤0.01% | 1967 |
|
|
2020
Q3 | $337K | Buy |
+4,026
| New | +$337K | ﹤0.01% | 2682 |
|